Glaukos Corp (GKOS, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. Glaukos Corp has a market cap of $1.92 billion; its shares were traded at around $44.06 with a P/E ratio of 169.47 and P/S ratio of 7.12.
For the last quarter Glaukos Corp reported a revenue of $65.8 million, compared with the revenue of $54.08 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $237.0 million, an increase of 30.7% from last year. For the complete 30-year financial data, please go here.. For the last five years Glaukos Corp had an average revenue growth rate of 38.3% a year.
The reported diluted earnings per share was 37 cents for the year. The Glaukos Corp had an operating margin of -21.22%, compared with the operating margin of -7.17% a year before. The 10-year historical median operating margin of Glaukos Corp is -10.77%. The profitability rank of the company is 5 (out of 10).
At the end of the fiscal year, Glaukos Corp has the cash and cash equivalents of $62.4 million, compared with $29.8 million in the previous year. The long term debt was $72.6 million. Glaukos Corp has a financial strength rank of 6 (out of 10).
CFO Recent Trades:
- CFO, SVP Corporate Development Joseph E Gilliam sold 3,750 shares of GKOS stock on 02/12/2020 at the average price of $68.5. The price of the stock has decreased by 35.68% since.
For the complete 20-year historical financial data of GKOS, click here.
